Is sorafenib patented?
Yes. Sorafenib was originally protected by patents, and the earliest patent terms have largely expired in most jurisdictions. However, patents and other exclusivity protections can also persist through later filings (for example, new formulations, specific uses, or manufacturing/process claims), depending on the country and the patent family.
When did sorafenib’s original patents expire?
Specific expiry dates depend on the jurisdiction and the exact patent family. In general, sorafenib’s core patent coverage is tied to the original filing and grant timelines, which are typically many years in the past, meaning the original “first-generation” protection has largely ended.
Are there still patents on sorafenib in 2026?
They can be. Even if the first patents expired, some countries may still have active patents related to:
- particular formulations or dosing presentations
- manufacturing processes
- additional indications or combinations
- improvements covered by later patent filings
To confirm whether any sorafenib patents are currently active where you are (or for a specific product), you need the country and product identifier.
How can you check if a specific sorafenib product is still under patent?
The most practical approach is to search by:
- the specific country (e.g., US, EU, UK, India, etc.)
- the company/brand or generic name and strength (because different products can rely on different patent sets)
- the underlying patent family (INPADOC/espacenet-style searches help track family members across jurisdictions)
Why does this matter for generics and biosimilars?
If active patents exist for sorafenib (on formulation/process/indication), generic entrants can be delayed in some countries unless they can rely on patent carve-outs or challenge the patents. This is why patent status varies by market.
What do you need to know to get a precise answer?
If you tell me the country (and whether you mean Nexavar or a generic), I can narrow the answer to the likely patent landscape for that specific market.